Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid

The resistance of melanoma to BRAF inhibitors remains a tough clinical challenge. In order to explore the underlying mechanism of drug resistance in melanoma, we established the resistant cell line to vemurafenib, and assessed the changes of drug-resistant cells on proliferation, apoptosis, oxidativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Ming, Wang, Lu, Gao, Zi-Xu, Deng, Xin-Yi, Shen, Kang-Jie, Li, Yan-Lin, Ding, Yi-Teng, Wei, Chuan-Yuan, Gu, Jian-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275918/
https://www.ncbi.nlm.nih.gov/pubmed/36700470
http://dx.doi.org/10.1080/21655979.2022.2080385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275918/
https://www.ncbi.nlm.nih.gov/pubmed/36700470
http://dx.doi.org/10.1080/21655979.2022.2080385

Ejemplares similares